🇺🇸 FDA
Pipeline program

LN-145

IOV-LUN-202

Phase 2 mab active

Quick answer

LN-145 for Metastatic Non Small Cell Lung Cancer is a Phase 2 program (mab) at IOVANCE BIOTHERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
IOVANCE BIOTHERAPEUTICS, INC.
Indication
Metastatic Non Small Cell Lung Cancer
Phase
Phase 2
Modality
mab
Status
active

Clinical trials